HUMANISED ANTI-CXCR4 ANTIBODIES FOR TREATING CANCER Russian patent published in 2016 - IPC C07K16/28 

FIELD: biochemistry.

SUBSTANCE: invention relates to biochemistry. Described is a group of inventions, which includes a humanised antibody and its derivative compound or functional fragment, capable of specifically binding with CXCR4, method of producing said antibody or its derivative compound or its functional fragment, isolated nucleic acid, vector and a host mammal, for producing said antibody or its derivative compound or its functional fragment, pharmaceutical composition exhibiting activity of specific binding with CXCR4, method of detecting in vitro presence of CXCR4-expressing tumour and a kit for in vitro detection of CXCR4. In one version antibody comprises CDR-H1 with amino acid sequence SEQ ID №4, CDR-H2 with SEQ ID №5, CDR-H3 with SEQ ID №6, CDR-L1 with SEQ ID №7, CDR-L2 with SEQ ID №8, CDR-L3 with SEQ ID №9.

EFFECT: invention widens range of antibodies binding to CXCR4.

20 cl, 76 dwg, 10 tbl, 31 ex